Almost exactly one year after the SEC announced a record $600 million insider trading settlement with hedge fund advisory firm CR Intrinsic Investors, an affiliate of S.A.C. Capital Advisors, it announced today that it has charged a former former analyst at CR Intrinsic with insider trading based on nonpublic information that he obtained about an unrelated pair of technology companies.

The previous March 2013 settlement with CR Intrinsic related to an alleged insider trading scheme involving a clinical trial for an Alzheimer's drug being jointly developed by two pharmaceutical companies, Elan and Wyeth. Today's settlement with former CR Intrinsic analyst Ronald N. Dennis alleges that Dennis received inside information from two fellow hedge fund analysts concerning (a) quarterly earnings announcements by Dell Inc., and (b) an impending acquisition of Foundry Networks by another technology company. The SEC alleges that by trading on this information, Dennis enabled hedge funds managed by CR Intrinsic and SAC Capital to generate approximately $3.2 million in profits and avoided losses in Dell stock, and $550,000 in profits from the purchase of Foundry stock.

Dennis agreed to settle the SEC's claims against him. According to the SEC, Dennis has agreed to be barred from the securities industry and will pay more than $200,000 to settle the case. Sanjay Wadhwa, senior associate director of the SEC's New York Regional Office, commented that Dennis' had failed to comply with insider trading laws “like several others before him at S.A.C. Capital." Wadhwa added that Dennis' "actions have cost him the privilege of working in the hedge fund industry ever again.”

Topics